RATIONALE: Childhood is connected with the gradual maturation of systemic and mucosal immunity and one of the consequences of such immune immaturity are the recurrent respiratory tract infections. One of the most common forms of chronic focal infections leading to many health consequences is adenoid hypertrophy (AH). The connection between adenoid hypertrophy and immune system is bidirectional. METHODS: We analyzed the characteristics of immune system and atopic status of the children with AH requiring adenoidectomy. Altogether, 72 children with AH (48 boys, 66.7%; aged 4.562.2 years) and 17 healthy children were included. RESULTS: Results of the cellular immunity did not show any significant deviations, however, 6 months after surgery, lymphocytes number declined to normal values. IgG1, IgG2, total IgE and complement components (C3 and C4) were significantly increased, probably as a consequence of chronic antigenic stimulation. In 19% of the children, complete mannose-binding lectin deficiency (MBL) was detected. In the rest of the children, 6 months after surgery, MBL concentrations significantly decreased. Atopy was detected in 83% children. The majority of them were sensitized against house dust mite and cat dander. Atopy and passive smoking showed deteriorating effects on the parameters of systemic humoral immunity and supported the airway colonization by pathogenic bacteria. CONCLUSIONS: Immune system is affected by chronic antigenic stimulation in children with adenoid hypertrophy. Surgical removal of AH normalized immune functions. Moreover, atopy and passive smoking could be considered as important risk factors for AH development and negative changes in mucosal microbiome. RESULTS: Thirty-eight probands with clinical PIDs were tested. Among these, 18% (7/38) were identified to have disease causing variants, detected in 7 genes, including HAX1, LRBA, RAC2, STAT1, CXCR4, ATM and RAG1. Results of proband testing led to further diagnosis of siblings in 2 families. Four additional probands were identified to have disease-causing variants, however molecular results were inconclusive based on expected inheritance and/or insufficient evidence. Two other probands were identified with variants in genes of clinical relevance, but were initially classified as inconclusive by the laboratory due to lack of data. Treatment was altered based on molecular testing results including starting immunomodulator therapy (abatacept for LRBA deficiency) and referrals for stem cell transplantation. Mean turnaround time for test results was 7.5 weeks. An average of 8.5 variants of unknown significance (VUSs) per sample were detected. CONCLUSIONS: Molecular testing in addition to clinical expertise and functional immunologic studies is helpful for diagnosis and treatment of PIDs. Panel testing brings faster and more comprehensive genetic evaluation for suspected cases. High rates of VUSs can be difficult to interpret, requiring clinician correlation, but may eventually resolve with increased PID-related genetic testing and data sharing within the specialty. ) mg/ml versus 31. 49 (24.75-37.15) mg/ ml, p<0.01), and greater TLR 4 on monocytes 4.73 (3.21-5.34) MFI versus 2.42 (2.18-2.65) MFI (p<0.01). In ABU anti-ET-Ig G (p<0.01) and anti-ET-Ig A (p<0.05) were greater than normal, but anti-ET-Ig M levels and TLR 4 were normal. Hs-CRP in DM2 was greater than controls, but no differences between LP and ABU (r>0.05). CONCLUSIONS: Interaction of LPS with LPB with neutralization of LPS by specific antibodies and elevated levels of TLR 4 expression occur during UTI in DM2 patients. High antibody response to LPS and normal TLR 4 expression characterize ABU in DM2 patients. 
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